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Background: The CYP7A1 gene polymorphism has been reported to be associated with gallbladder stone disease
(GSD) and serum lipid levels, but the results were inconsistent. This meta-analysis aimed to evaluate the influence
of the -204A > C polymorphism in the promoter of CYP7A1 gene on the GSD and serum lipid levels.
Methods: According to inclusion/exclusion criteria, eligible studies on CYP7A1 gene -204A > C polymorphism of
serum lipid levels and the risk of GSD were retrieved. Depending on the between-study heterogeneity, the fixed- or
random-effects model was applied, and the data were analyzed using the RevMan software (V5.2).
Results: Five studies totaling 830 GSD patients and 882 healthy controls were used to evaluate the relation of
CYP7A1 -204A > C polymorphism with GSD. Overall comparison of alleles A with C in all study population yielded
5% but non-significant increased risk of GSD (OR = 1.05, 95% CI: 0.91 − 1.22, P = 0.48). Subgroup analysis by ethnic
differences did not show any association between CYP7A1 -204A > C polymorphism and GSD either. Four studies
totaling 802 cases and 691 controls were used to assess the relation of CYP7A1 -204A > C polymorphism with serum
lipid levels. All the subjects were from the Asian population. The pooled effects indicated that AC genotype had
higher levels of TG than AA (MD = -0.42, 95% CI: -0.76 − -0.08, P = 0.01). CC genotype in cases had higher levels of
TC (MD = 0.65, 95% CI: 0.25 − 1.05, P = 0.001) and LDL-C (MD = 0.40, 95% CI: 0.06 − 0.73, P = 0.02) than AA, AA
(MD = -0.35, 95% CI: -0.60 − -0.10, P = 0.007) and AC (MD = −0.35, 95% CI: -0.61 − -0.08, P = 0.01) genotypes in
controls had higher levels of TC than CC, and AA genotype in controls had higher levels of HDL-C than CC
(MD = -0.15, 95% CI: -0.21 − -0.09, P < 0.00001).
Conclusions: The CYP7A1 -204A > C polymorphism is significantly associated with serum lipid levels in Asian
population, but not gallbladder stone disease.
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Gallbladder stone disease (GSD) is one of the most com-
mon diseases in many countries. The formation of GSD
is multi-factorial, with a complex interaction between
the environment factors and multiple susceptible genes
[1]. Data from the Swedish Twin Registry showed that
the contribution of hereditary factors to symptomatic
GSD accounts for 25% [2].* Correspondence: zhaoyanjiang@gmail.com
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unless otherwise stated.Oversaturatation of biliary cholesterol is the requisite
biochemical defect for the formation of GSD [3]. This
pathophysiological change is induced by either hypersecre-
tion of biliary cholesterol or decreased secretion of bile
acids. Both the cholesterol secreted into bile and the bile
acids converted from cholesterol in the liver are involved
in the regulating cholesterol homeostasis. Cholesterol
7α-hydroxylase (CYP7A1) is the rate-limiting enzyme of
hepatic bile acid synthesis. A rare mutation of CYP7A1
gene was reported to account for the incidence of gall-
stone disease as well as familial hypercholesterolemia in
a family [4]. Various genetic variations have also been
reported in CYP7A1 gene [5,6]. The polymorphism of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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was reported to affect its enzyme activity [7]. A number
of studies have been focused on the association between
the -204A > C polymorphism and metabolic disorders
of cholesterol and bile acid, including hypercholesterol-
emia, hypertriglyceridemia and GSD [8-13]. However,
the results are inconsistent and inconclusive due to
different study design, population, etc. Therefore, we
performed this meta-analysis to evaluate the relation of




We conducted a systematic publication search that
published in English or Chinese via pubic database
PubMed, Embase, ISI Wed of Knowledge, China Bio-
logical Medicine (CBM) and China National KnowledgeFigure 1 Flow diagram of search strategy and study selection.Infrastructure (CNKI) up to February 2014 using the fol-
lowing terms: “Cholesterol 7α-hydroxylase”, “CYP7A1”,
“rs3808607 (-204A > C) polymorphism”, “gallbladder
stone disease”, “dyslipidemia” and “serum lipid levels”.
The search was restricted to humans. All eligible stud-
ies were retrieved and the full text of the articles was
examined to make sure the data of interest were in-
cluded. If multiple reports from the same patients were
found, only the publication with the most complete
data set was included.
Inclusion and exclusion criteria
Studies that we identified were required to meet the fol-
lowing criteria: (1) study on -204A > C polymorphism of
CYP7A1 gene, serum lipid levels and the risk of GSD;
(2) case–control study that used either hospital-based
or population-based designs; (3) reporting at least one
relevant outcomes of association between genotype and
Figure 2 Forest plot of the association between CYP7A1 -204A > C polymorphism and GSD risk. (Allelic model: A vs C).
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including total cholesterol (TC), high-density lipoprotein
cholesterol (HDL-C), low-density lipoprotein cholesterol
(LDL-C), and triglycerides (TG). Studies were excluded
if they were case-only studies, case reports, or published
abstracts from meeting.Extracted information
Two investigators (QC and ZQW) independently ex-
tracted the following information from all selected
articles: first author, year, country, ethnicity, eligible
subjects, study design, methods to diagnosis, genotyping
information (genotyping method, number of genotypes,
genotype distribution in cases and controls), association
between genotypes and serum lipid parameters and the
risk of GSD, etc. Ethnic backgrounds were categorized
as Caucasian or Asian. The units of measurements used
in this study were transformed into the standard mea-
surements units.Table 1 Comparisons of A vs C in allele, genotype
dominant and recessive models for GSD risk
Comparisons Pooled OR (95% CI) Z (P) I2 (%)
A vs C 1.05 (0.91,1.22) 0.70 (0.48) 46
AA vs CC 1.06 (0.79,1.42) 0.42 (0.68) 41
AC vs CC 0.92 (0.70,1.21) 0.60 (0.55) 0
AA + AC vs CC 0.97 (0.76,1.25) 0.22 (0.82) 12
AA vs AC + CC 1.15 (0.92,1.43) 1.25 (0.21) 31Statistical analysis
Before estimating the relationship between the CYP7A1
-204A > C polymorphism and GSD and serum lipid
levels, we tested whether the genotype frequencies of the
controls were in Hardy-Weinberg equilibrium (HWE)
using a χ2 test (P > 0.05) [14]. We carried out statistical
analysis by the software Review Manager (V5.2) for Mac
Os X. Continuous variables were expressed as mean
difference (MD) with 95% confidence intervals (CI).
Dichotomous variables were expressed as odd ratio (OR)
with 95% CI. Subgroup analysis for ethinicity (Asian and
Caucasian) and population (case and control) was con-
ducted. The chi-square test based on Q test and I2 statis-
tics were used to assess the hererogeneity among studies
[15-17]. When the Q test was significant (P < 0.05) or I2 >
50%, indicating the presence of heterogeneity, a random-
effects model (the DerSimonian & Laird method) was
used [18]; otherwise, the fixed-effects model (the Mantel-
Haenszel method) was used [19]. If enough studies were
identified, funnel plots were to be used to investigate
reporting biases.Results
Studies and populations
The literature search identified 16 potentially relevant
papers. Seven papers were excluded and 9 papers (5 in
English [5,11,12,20,21], 4 in Chinese [22-25]) were in-
cluded finally. A flow diagram of the study selection
process is presented in Figure 1. All of the studies had
been approved by the Ethics Committee of their affilia-
tions, in accordance with the Helsinki Declaration of 1975
as revised in 1983, and all subjects had given informed
consent. The present study was approved by the Ethics
Committee of the Ruijin Hospital, Shanghai JiaoTong
University School of Medicine. Five of the eligible
studies including 830 gallbadder stone disease patients
and 882 controls were used to evaluate the relation of
CYP7A1 -204A >C polymorphism with GSD [5,11,12,21,23].
Four of the eligible studies including 802 cases and 691
controls were used to assess the association between
CYP7A1 -204A > C polymorphism and serum lipid levels
[20,22,24,25]. Many studies have proved that serum lipid
concentrations are strongly correlated to the risk of coron-
ary artery disease (CAD), two papers contained the data of
CAD was elected for the meta-analysis [20,24]. The main
characteristics of each study are presented in Additional
file 1: Table S1.
Analyses of the risk of GSD
In allelic model, the eligible compared groups were
pooled with the fixed-effects models and the comparison
showed that the CYP7A1 -204A allele was related to a
nonsignificant 5% increased risk of GSD (OR = 1.05,
95% CI: 0.91 − 1.22, P = 0.48) (Figure 2). No significance
was observed in genotypic models for comparisons of
Figure 3 Forest plot of the association between CYP7A1 -204A > C polymorphism and serum TG levels. (Genetic model: AA vs AC).
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(OR = 0.92, 95% CI: 0.70 − 1.21, P = 0.55) genotypes
with CC genotype, respectively, as well as in dominant
(OR = 0.97, 95% CI: 0.76 − 1.25, P = 0.82) and recessive
(OR = 1.15, 95% CI: 0.92 − 1.43, P = 0.21) models
(Table 1).
Considering the ethnic differences might bias the over-
all association, we separated the studies in Asian and
Caucasian. There was no significant change in all sub-
groups either (data not shown).
Analyses of the serum lipid levels
In the present study, we included four studies in which
all the subjects were Asian population. As shown in
Figure 3, the pooled effects indicated that AC geno-
type had higher levels of TG than AA (MD= −0.42, 95%
CI: -0.76 − -0.08, P = 0.01). Meanwhile, the magni-
tude of association was largely strengthened in casesFigure 4 Forest plot of the association between CYP7A1 -204A > C po(MD = -0.72, 95% CI: -1.09 − -0.35, P = 0.0001). As shown
in Figure 4, AA genotype had higher levels of TC than CC
in controls (MD = -0.35, 95% CI: -0.60 − -0.10, P = 0.007),
but not in the recessive models in cases (MD = 0.65, 95%
CI: 0.25 − 1.05, P = 0.001). AC genotype had higher
levels of TC than CC in controls (MD = −0.35, 95%
CI: -0.61 − -0.08, P = 0.01; Figure 5). There was no signifi-
cant difference in the levels of TC between AA and AC
genotypes (MD= −0.09, 95% CI: −0.31—0.13, P = 0.40).
Compared with CC genotype in controls, AA had higher
levels of HDL-C (MD = −0.15, 95% CI: -0.21 − -0.09,
P < 0.00001; Figure 6). For the comparison of LDL-C
levels, CC genotype was significantly higher than AA in
cases (MD = 0.40, 95% CI: 0.06 − 0.73, P = 0.02; Figure 7).
Test of heterogeneity
For the analyses of the serum lipid levels, the I2 values
of heterogeneity were greater than 50% and P values oflymorphism and serum TC levels. (Genetic model: AA vs CC).
Figure 5 Forest plot of the association between CYP7A1 -204A > C polymorphism and serum TC levels. (Genetic model: AC vs CC).
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models above in the overall populations, indicating
that significant between-study heterogeneity among
the studies. In order to explore the possible sources of
heterogeneity, we seperated the studies into cases and
controls. Thereafter, the between-study heterogeneity
was obviously reduced or even gone under the sub-
group analyses.
Discussion
To our knowledge, this is the first meta-analysis to
evaluate the association between CYP7A1 -204A > CFigure 6 Forest plot of the association between CYP7A1 -204A > C popolymorphism and GSD and serum lipid levels. In this
study, we collected data from 9 papers to evaluate the
association of CYP7A1 gene polymorphisms with GSD
and serum lipid levels. The results showed that -204A > C
polymorphism of CYP7A1 gene related with difference
in serum lipids. However, this polymorphism was not
associated with GSD.
The -204A > C of CYP7A1 gene is one of the most fre-
quently studied polymorphisms for the association with
GSD. Our previous study showed that A allele of CYP7A1
gene might be considered as risk gene for GSD in Chinese
patients [21]. Later on, Juzyszyn et al. [11] and Strivastavalymorphism and serum HDL-C levels. (Genetic model: AA vs CC).
Figure 7 Forest plot of the association between CYP7A1 -204A > C polymorphism and serum LDL-C levels. (Genetic model: AA vs CC).
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not confirm such association. The samples sizes in the rest
studies were relatively small [12,23]. Herein, by pooling all
the previous studies, we demonstrated a lack of associ-
ation between this polymorphism with GSD.
An obvious difference of gallstone prevalence between
populations is present due to different ethnicities. GSD is
highly prevalent in Pima Indians, Hispanic, relatively lower
in Asian and the lowest in African [26]. The frequency of
A allele of -204A > C polymorphism in gallstone-free sub-
jects is lower in Asian population, 18.09% in Chinese [23],
high up to 60.2% in Indian [5]. In Caucasian population,
its frequency is between 52.1 [11] and 72.28% [12]. How-
ever, when the population was divided into Asian and
Caucasian, we did not find any association of -204A > C
polymorphism with GSD existed in either ethnicity.
The second aim of our study is to evaluate the associ-
ation between -204A > C polymorphism and serum lipids.
The -204A > C polymorphism was shown to be associated
with plasma LDL-C concentrations [8,27]. Our previous
study also found that individuals with A allele tended to
have lower LDL-C concentrations [21]. While in this
meta-analysis, we found that the genotype AA had sig-
nificantly lower levels of LDL-C than genotype CC only
in patients, but not in controls. Couture et al. [8] de-
scribed that the genotype AC had significantly higher
TG levels than the genotype CC in women and the C
variant was also associated with an increased TC/HDL-
C ratio in men. Hofman et al. [10] found a significant
34% increase of serum TG levels in genotype AA as
compared with genotype CC in a healthy normolipidaemic
male population. However, our meta-analysis showed that
genotype AC had higher TG levels than genotype AA,allele A carriers in healthy population had higher TC
levels than genotype CC, but not in the recessive models
in cases, and genotype AA had higher HDL-C levels than
genotype CC in controls.
Some limitations of this meta-analysis merit serious
consideration. First, only the papers published in English
and Chinese were included in our study. Any data re-
ported in other languages could not be included which
might bring some bias. Second, no adequate information
such as source of the subjects, anti-dyslipidemia drug
and etc. could be obtained in this meta-analysis. These
factors might bring in several possible sources of hetero-
geneity. Third, most studies have recruited age > 40 years,
for whom environmental factors are likely to contribute
more prominently than the genetic component during
the development of GSD and dyslipidemia.
In conclusion, this meta-analysis did not found any
association between CYP7A1 -204A > C polymorphism
and GSD. However, this polymorphism was closely
related with serum lipid levels.Additional file
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